Rapid Micro Biosystems (NASDAQ:RPID) CEO Robert Jr. Spignesi Sells 17,922 Shares

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CEO Robert Jr. Spignesi sold 17,922 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.11, for a total transaction of $73,659.42. Following the completion of the sale, the chief executive officer owned 1,169,848 shares in the company, valued at $4,808,075.28. This represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Rapid Micro Biosystems Price Performance

Shares of NASDAQ:RPID traded down $0.66 during trading on Friday, hitting $2.76. 602,496 shares of the company were exchanged, compared to its average volume of 272,192. The company has a quick ratio of 2.95, a current ratio of 4.23 and a debt-to-equity ratio of 0.42. Rapid Micro Biosystems, Inc. has a 1-year low of $1.86 and a 1-year high of $4.94. The company has a market capitalization of $122.33 million, a P/E ratio of -2.75 and a beta of 1.38. The business’s 50 day moving average is $3.98 and its 200-day moving average is $3.54.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%.The firm had revenue of $11.28 million during the quarter, compared to analyst estimates of $10.93 million. Equities analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

Trending Headlines about Rapid Micro Biosystems

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Recorded revenue growth and raised outlook: RPID reported record Q4 ($11.3M) and full‑year 2025 ($33.6M) revenue with management providing 2026 revenue guidance of $37.0M–$41.0M and expected system placements, signaling continued commercial traction and scale potential. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer orders: RPID announced follow‑on multi‑system orders (Samsung Biologics) and expanded deployments (Amgen), reinforcing demand from big pharma/CDMO customers and validating the Growth Direct platform in large manufacturing networks. GlobeNewswire: Follow-on Multi‑System Order from Samsung Biologics
• Positive Sentiment: Analyst/coverage note highlights adoption: Independent analysis points to big‑pharma adoption as a key growth driver, which supports upside from recurring placements, service and consumables revenue over time. Seeking Alpha: Big Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance sits near consensus but leaves execution risk: 2026 revenue range is centered near analyst expectations (~$39M midpoint) but the wide range and modest gross margin guidance (~20%) leave outcomes dependent on system placements and margin expansion. Yahoo Finance: Q4 2025 Earnings Report Preview
• Neutral Sentiment: Earnings call highlighted growth vs. pressure trade‑offs: Management framed the quarter as progress on commercial adoption but noted margin and scaling pressures—mixed messaging that can moderate near‑term enthusiasm. TipRanks: Earnings Call Balances Growth, Pressure
• Negative Sentiment: EPS missed despite revenue beat: Q4 EPS came in at ($0.28) vs. consensus ($0.23) miss, and the company remains unprofitable with negative margins—an ongoing profitability concern for investors. MarketBeat: Q4 2025 Earnings and Call
• Negative Sentiment: Recent insider selling by CEO, CFO and COO: Multiple disclosed Form 4 sales by senior executives (March filings) may amplify selling pressure or raise investor concerns about insider conviction. SEC Form 4: CEO Insider Sale

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Rapid Micro Biosystems has a consensus rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Rapid Micro Biosystems

Several institutional investors have recently added to or reduced their stakes in the business. Evernest Financial Advisors LLC lifted its position in shares of Rapid Micro Biosystems by 355.1% during the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company’s stock valued at $669,000 after acquiring an additional 156,234 shares during the period. 683 Capital Management LLC bought a new stake in Rapid Micro Biosystems in the fourth quarter valued at $350,000. Millennium Management LLC acquired a new position in shares of Rapid Micro Biosystems during the fourth quarter valued at about $338,000. Informed Momentum Co LLC bought a new position in shares of Rapid Micro Biosystems during the 4th quarter worth about $224,000. Finally, Jane Street Group LLC boosted its position in shares of Rapid Micro Biosystems by 176.1% during the 4th quarter. Jane Street Group LLC now owns 105,301 shares of the company’s stock worth $305,000 after purchasing an additional 67,161 shares in the last quarter. 52.60% of the stock is owned by institutional investors and hedge funds.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.